Amicus Therapeutics, Inc. (FOLD)
Whether directors and officers of Amicus Therapeutics, Inc. (FOLD) breached their fiduciary duties to the company and its shareholders.
Investigation
02/23/2022
Initial Lawsuit
03/24/2022
Lawsuit Progression
06/22/2022
Did Vertiv Holdings Co mislead investors with its management’s consistent underestimation of inflation and supply chain constraints?
This post is open for investors to gather facts, and findings and track their exposure to related lawsuits. We invite investors and shareholders to contribute to this investigation for their own benefit, add events to the factual timeline below and vote on events’ pertinence.
A lawsuit was subsequently filed. We will update this post as it unfolds.
02/23/2022
Vertiv reports its Q4 2021 financial results, impacted by “Inflationary and Supply Chain Pressures” along with “significant pricing actions” implemented at end of 2021 and early 2022.
“We consistently underestimated inflation and supply chain constraints for both timing and degree, which dictated a tepid 2021 pricing response. We learned a hard lesson from our slow response in 2021, and we acted decisively late last year and early this year with aggressive price actions. We expect that the impact of these actions will progressively show in our 2022 profitability, with each quarter sequentially better than the previous quarter, and that our second half 2022 results will be strong – setting the stage for consistently improving profitability going forward.” Rob Johnson, Vertiv’s Chief Executive Officer.
Stock Impact
Close | Previous close | Price variation | Percentage variation |
---|---|---|---|
$12.38 | $19.57 | $-7.19 | -36.74% |
A Vertiv Holdings Co shareholder filed a securities class action on behalf of persons and entities that: (a) purchased shares of Vertiv’s class A common stock between February 24, 2021, and February 23, 2022, inclusive; and/or (b) purchased Vertiv shares in or traceable to the company’s secondary public offering of class A common stock conducted on or around November 4, 2021 (SPO).
According to the complaint, defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the company’s business, operations, and prospects. Specifically, defendants allegedly failed to disclose to investors that:
(i) Vertiv’s “pricing initiatives” were ineffective and the company’s sales force was not capable of driving higher pricing and passing costs on to customers;
(ii) Instead, the sales team had resorted to discounting in order to drive
sales and build the company’s backlog, which resulted in lower margins and profitability.
06/22/2022
The court issued an order appointing the lead plaintiff and lead counsel.
Whether directors and officers of Amicus Therapeutics, Inc. (FOLD) breached their fiduciary duties to the company and its shareholders.
Whether directors and officers of LegalZoom.com, Inc. (LZ) breached their fiduciary duties to the company and its shareholders.
Whether directors and officers of Builders FirstSource, Inc. (BLDR) breached their fiduciary duties to the company and its shareholders.
Whether directors and officers of Kewaunee Scientific Corporation (KEQU) breached their fiduciary duties to the company and its shareholders.
Whether directors and officers of Inari Medical, Inc. (NARI) breached their fiduciary duties to the company and its shareholders.
Whether directors and officers of Payoneer Global Inc. (PAYO) breached their fiduciary duties to the company and its shareholders.